# Practical Feasibility Assessment: TYROBP-SYK Hypotheses
## Hypothesis 1: Downstream Effector Specificity (Revised confidence: 0.52)
### Druggability: MODERATE
| Component | Status | Notes |
|-----------|--------|-------|
| PI3K p110δ | High | Multiple inhibitors approved (idelalisib, duvelisib) |
| CARD9 | Low | No selective inhibitors; challenging target |
| Selective branching | Very Low | No tool compounds exist to test this premise |
**Core Problem:** The hypothesis requires *simultaneously* enhancing PI3K-Akt while sparing/blocking CARD9. Current pharmacology cannot achieve this selectivity at the pathway level. We'd need bifunctional molecules or downstream effector modulators that don't exist.
### Existing Compounds
- PI3K inhibitors: FDA-approved for hematologic malignancies; significant toxicity (immune-related adverse events)
- CARD9 inhibitors: None in pipeline
- SYK inhibitors: Fostamatinib (approved for ITP), but can't selectively modulate branches
### Development Cost & Timeline
- **Cost:** $200-400M (de novo compound development)
- **Timeline:** 10-15 years (novel mechanism, no established regulatory pathway)
- **Risk:** High probability of failure in Phase II given pathway complexity
### Safety Concerns
- **PI3K inhibition:** colitis, hepatotoxicity, myelosuppression—poor CNS penetration anyway
- **Systemic immune suppression:** Even if we wanted PI3K enhancement, peripheral toxicity is severe
- **On-target effects:** Both pathways are ubiquitous; selectivity is the central unsolved problem
### Verdict: **Low near-term feasibility.** Requires fundamental tool compound development. Recommend testing with available tools (PI3Kδ conditional knock-in models) before committing resources.
---
## Hypothesis 2: Disease Stage-Dependent Dual Role (Confidence: 0.68)
### Druggability: MODERATE-HIGH
| Component | Status | Notes |
|-----------|--------|-------|
| TREM2 agonist | High | Multiple candidates in development |
| TYROBP signaling | Moderate | Downstream of TREM2, less directable |
| Stage determination | Operational gap | No validated biomarker exists |
**Core advantage:** TREM2 agonism is the most advanced therapeutic approach for this axis. AL002 (ALX Oncology), JNJ-77342102 ( Janssen), and others are in Phase I/II for Alzheimer's.
### Existing Compounds & Trials
| Compound | Company | Stage | Mechanism |
|----------|---------|-------|-----------|
| AL002 | ALX Oncology | Phase II (Alzheimer's) | TREM2 agonist |
| JNJ-77342102 | Janssen | Phase I | TREM2 agonist |
| Tiligemastat | Alector | Phase II | TREM2 agonist |
| HOff233 | Hoffmann-La Roche | Phase I | TREM2 agonism |
### Development Cost & Timeline
- **Cost:** $150-300M (if leveraging existing programs)
- **Timeline:** 5-8 years (existing platforms)
- **Risk:** Moderate—TREM2 agonism has shown safety but unclear efficacy signal
### Safety Concerns
- **Cytokine dysregulation:** TREM2 modulation affects immune cell survival and activation
- **Infection risk:** TREM2 affects macrophage function; theoretical susceptibility to intracellular pathogens
- **Timing toxicity:** Enhanced signaling early may accelerate neurodegeneration if staging is miscalibrated
### Verdict: **Highest feasibility.** This hypothesis is testable within current clinical programs. The critical experiment is biomarker stratification (CSF TREM2, PET-microglial activation) to identify early vs. late patients and correlate with treatment response.
---
## Hypothesis 3: Cell-Type Specific Effects (Confidence: 0.61)
### Druggability: VERY LOW
| Component | Status | Notes |
|-----------|--------|-------|
| Microglia-selective delivery | Unresolved | No validated strategy |
| SYK cell-type targeting | Not feasible | SYK inhibitors cannot distinguish cell origin |
| BBB penetration | Competing need | Must penetrate CNS but not affect peripheral |
**Core Problem:** The therapeutic paradox requires delivering opposing effects to microglia vs. monocytes. No existing delivery technology can achieve this without cell-type-specific promoters or targeting ligands.
### Existing Compounds
- Fostamatinib: Penetrates BBB but hits both microglial and peripheral SYK
- No selective microglial SYK modulators exist
### Development Cost & Timeline
- **Cost:** $500M+ (requires platform development)
- **Timeline:** 15+ years
- **Risk:** Extremely high
### Safety Concerns
- **Dual targeting:** Cannot separate beneficial microglial from harmful peripheral effects with current tools
- **Off-target peripheral toxicity:** Systemic SYK inhibition affects platelets (SYK-dependent ITP pathway), causing bleeding risk
### Verdict: **Not currently feasible.** Worth pursuing as a platform technology (microglia-specific delivery vehicles) but not viable as an immediate therapeutic strategy.
---
## Hypothesis 4: TREM2-Independent TYROBP Signaling (Confidence: 0.58)
### Druggability: LOW
| Component | Status | Notes |
|-----------|--------|-------|
| TREM2-independent interactors | Poorly characterized | PILRy, TREM2R, others undefined |
| Selective pathway inhibition | Not possible | No tool compounds exist |
| Target identification | Research gap | Requires systematic interactome mapping |
**Core Problem:** We don't know enough. The TREM2-independent TYROBP interactome is insufficiently characterized in human microglia to